依折麦布联合辛伐他汀对高脂血症合并颈动脉粥样硬化的治疗作用  

The effect of Ezetimibe Combined with Simvastatin on Carotid Arterial Intima-media Thickness in Patients with Carotid Atherosclerosis

作　　者：国希云[1] 李芳 邓娴[1] 阳蒙蒙 路秀文[1] 李丽娜[1] 王曙霞[1] 陈德友[1] 

机构地区：[1]解放军总医院门诊部干部诊疗科,北京市100853 [2]总后第二门诊部,北京市100071

出　　处：《中国分子心脏病学杂志》2016年第2期1643-1645,共3页Molecular Cardiology of China

基　　金：国家科技支撑计划(2013BAH14F03;2013BAH05F05);国家自然科学基金(81100160)

摘　　要：目的观察依折麦布联合辛伐他汀对高脂血症合并动脉粥样硬化患者颈动脉内膜中层厚度(carotid arterial intima-media thickness,CIMT)的影响。方法采用随机、双盲研究,入选我院2013年6月至2014年8月门诊的高脂血症合并颈动脉粥样硬化患者,共108例,平均年龄67.4±9.3岁。将108例患者随机分为治疗组与对照组。所有患者均可正常饮食,继续原发病的常规治疗,停用其它降脂药物2周,以减少其它降脂药物对疗效判断的干扰,治疗组54例患者在辛伐他汀10 mg/d的基础上加用依折麦布5 mg/d,对照组54例患者使用辛伐他汀10 mg/d治疗4个月。均每日服药1次,于每晚入睡前或晚餐后3小时服用.4个月后以超声观察CIMT的变化,并采空腹静脉血,测定总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C),高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)。结果冶疗组与对照组的颈动脉内膜厚度及血脂水平均有明显下降,治疗组的颈动脉内膜中层厚度有下降更明显,从1.83±0.36mm下降至1.41±0.29mm,有统计学意义(p<0.01;且改善较对照组更明显(p<0.05),所有患者对依折麦布均能很好地耐受而且依从性较好,研究期间未发现药物相关严重不良反应。结论依折麦布联合辛伐他汀对高脂血症合并颈动脉粥样硬化的CIMT改善优于单用辛伐他汀组.并具有良好的安全性。Objective To investigate the effect Ezetimibe combined with Simvastatin on carotid arterial intima-media thickness in patients with Carotid Atherosclerosis.Methods In the randomized and dounle- blind trial,108 patients were with mean age of 67.4±9.3 enrolled from June 2013 to August 2014.The treatment group accepted Ezetimibe 5mg/d combined with Simvastatin 10mg/d,and the control group accepted Simvastatin 10mg/d for 4 months.Results The CIMT and serum TC.LDL- C and TG was reduced in treatment and control gruops after 4months therapy.The degree of better was higher of CIMT in the treatment group than control group,from 1.83±0.36 mm to 1.41±0.29 mm.Conclusion Treatment by Ezetimibe combined with Simvastatin could decrease carotid arterial intima-media thickness in patients with Carotid Atherosclerosis.

关 键 词：依折麦布 辛伐他汀 动脉粥样硬化 颈动脉 内膜中层厚度 

分 类 号：R589.2[医药卫生—内分泌] R543.4[医药卫生—内科学]